232 related articles for article (PubMed ID: 28878573)
21. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
[TBL] [Abstract][Full Text] [Related]
23. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
24. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
[TBL] [Abstract][Full Text] [Related]
27. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
[TBL] [Abstract][Full Text] [Related]
28. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
29. The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan.
Yamabe K; Singhal PK; Abe M; Dasbach EJ; Elbasha EH
Value Health Reg Issues; 2013 May; 2(1):92-97. PubMed ID: 29702859
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study.
Li Y; Lin YF; Wu X; Zhou X; Tian T; Guo Z; Fu L; Yang L; Lu Z; Fan S; Lu Y; Ke W; Zou H
Front Immunol; 2023; 14():1197191. PubMed ID: 37426648
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.
Mennini FS; Bonanni P; Bianic F; de Waure C; Baio G; Plazzotta G; Uhart M; Rinaldi A; Largeron N
Cost Eff Resour Alloc; 2017; 15():11. PubMed ID: 28701899
[TBL] [Abstract][Full Text] [Related]
32. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
33. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
34. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands.
Simons JJM; Vida N; Westra TA; Postma MJ
Vaccine; 2020 Jun; 38(30):4687-4694. PubMed ID: 32451211
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
37. Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China.
Zou M; Liu H; Liu H; Wang M; Zou Z; Zhang L
Front Immunol; 2023; 14():1119566. PubMed ID: 37051255
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model.
Dasbach EJ; Largeron N; Elbasha EH
Expert Rev Pharmacoecon Outcomes Res; 2008 Oct; 8(5):491-500. PubMed ID: 20528334
[TBL] [Abstract][Full Text] [Related]
39. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Jiang Y; Ni W; Wu J
BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
